✦ LIBER ✦

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

✍ Scribed by Farshid Dayyani; Hagop Kantarjian; Susan O'Brien; Sherry Pierce; Dan Jones; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 140 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25585

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug Discovery Research || Retinoic Acid

Drug Discovery Research || Retinoic Acid and Arsenic Trioxide Treatment in Acute Promyelocytic Leukemia: A Model of Oncoprotein Targeted Therapy

✍ Huang, Ziwei 📂 Article 📅 2007 🏛 John Wiley & Sons, Inc. ⚖ 364 KB 👁 2 views

A Phase 2 study of combination therapy w

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

✍ Mikkael A. Sekeres; Jaroslaw P. Maciejewski; Harry P. Erba; Manuel Afable; Ricki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

A single, high dose of idarubicin combin

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

✍ Mark A. Weiss; Timothy B. Aliff; Martin S. Tallman; Stanley R. Frankel; Matt E. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Background: The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. one option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense

A randomized trial of liposomal daunorub

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t